Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis

English version České info

Background:
The new 2010 World Health Organization (WHO) HIV treatment guidelines recommend earlier antiretroviral therapy (ART) initiation (CD4<350 cells/µl instead of CD4<200 cells/µl), multiple sequential ART regimens, and replacement of first-line stavudine with tenofovir. This paper considers what to do first in resource-limited settings where immediate implementation of all of the WHO recommendations is not feasible.

Methods and Findings:
We use a mathematical model and local input data to project clinical and economic outcomes in a South African HIV-infected cohort (mean age = 32.8 y, mean CD4 = 375/µl). For the reference strategy, we assume that all patients initiate stavudine-based ART with WHO stage III/IV disease and receive one line of ART (stavudine/WHO/one-line). We rank—in survival, cost-effectiveness, and equity terms—all 12 possible combinations of the following: (1) stavudine replacement with tenofovir, (2) ART initiation (by WHO stage, CD4<200 cells/µl, or CD4<350 cells/µl), and (3) one or two regimens, or lines, of available ART. Projected life expectancy for the reference strategy is 99.0 mo. Considering each of the guideline components separately, 5-y survival is maximized with ART initiation at CD4<350 cells/µl (stavudine/<350/µl/one-line, 87% survival) compared with stavudine/WHO/two-lines (66%) and tenofovir/WHO/one-line (66%). The greatest life expectancies are achieved via the following stepwise programmatic additions: stavudine/<350/µl/one-line (124.3 mo), stavudine/<350/µl/two-lines (177.6 mo), and tenofovir/<350/µl/two-lines (193.6 mo). Three program combinations are economically efficient: stavudine/<350/µl/one-line (cost-effectiveness ratio, US$610/years of life saved [YLS]), tenofovir/<350/µl/one-line (US$1,140/YLS), and tenofovir/<350/µl/two-lines (US$2,370/YLS).

Conclusions:
In settings where immediate implementation of all of the new WHO treatment guidelines is not feasible, ART initiation at CD4<350 cells/µl provides the greatest short- and long-term survival advantage and is highly cost-effective.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis. PLoS Med 7(12): e32767. doi:10.1371/journal.pmed.1000382
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000382

Souhrn

Zdroje

1. World Health Organization 2006 WHO HIV/AIDS Programme: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. Available: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 14 December 2009

2. World Health Organization 2010 Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed 3 August 2010

3. United States Department of Health and Human Services 2009 December 1 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 14 December 2009

4. European AIDS Clinical Society 2009 November Guidelines: clinical management and treatment of HIV infected adults in Europe. Available: http://www.europeanaidsclinicalsociety.org/guidelines.asp. Accessed 16 December 2009

5. World Health Organization 2009 Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Available: http://www.who.int/hiv/pub/tuapr_2009_en.pdf. Accessed 14 December 2009

6. Malawi Ministry of Health 2008 April Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi. Available: http://www.hivunitmohmw.org/Main/AntiretroviralTherapy. Accessed 18 November 2009

7. ChirwaZ

ChimbwandiraF

NjalaJ

MhangoE

MakombeS

2010 Rapid feasibility appraisal in Malawi for the introduction of revised WHO ART recommendations 2009. In: Program and Abstracts of the 28th International AIDS Conference. Vienna, Austria. Abstract WEAE0202

8. World Health Organization, Joint United Nations Programme on HIV/AIDS, United Nations Children's Fund 2008 September Epidemiological fact sheet on HIV and AIDS: core data on epidemiology and response, South Africa. September 2008 update. Available: http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_ZA.pdf. Accessed 14 December 2009

9. WalenskyRP

WoodR

WeinsteinMC

MartinsonNA

LosinaE

2008 Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 197 1324 1332

10. WalenskyRP

WolfLL

WoodR

FofanaMO

FreedbergKA

2009 When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151 157 166

11. GoldieSJ

YazdanpanahY

LosinaE

WeinsteinMC

AnglaretX

2006 Cost-effectiveness of HIV treatment in resource-poor settings—the case of Côte d'Ivoire. N Engl J Med 355 1141 1153

12. GoldMR

SiegelJE

RussellLB

WeinsteinMC

1996 Cost-effectiveness in health and medicine. New York Oxford University Press

13. Oanda Corporation. 2009 FXHistory: historical currency exchange rates. Available: http://www.oanda.com/currency/average. Accessed 14 December 2009

14. International Monetary Fund 2009 World economic outlook database, October 2009. Available: http://www.imf.org/external/pubs/ft/weo/2009/02/weodata/weoseladv.aspx?a=&c=199&s=NGDP_D. Accessed 14 December 2009

15. MathersCD

SadanaR

SalomonJA

MurrayCJ

LopezAD

2001 Healthy life expectancy in 191 countries, 1999. Lancet 357 1685 1691

16. DelfraissyJF

FlandreP

DelaugerreC

GhosnJ

HorbanA

2008 Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22 385 393

17. LosinaE

YazdanpanahY

Deuffic-BurbanS

WangB

WolfLL

2007 The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antivir Ther 12 543 551

18. ColeSR

HernanMA

RobinsJM

AnastosK

ChmielJ

2003 Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158 687 694

19. HammondR

HarryTC

2008 Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures—a meta-analysis. Int J STD AIDS 19 291 296

20. HolmesCB

WoodR

BadriM

ZilberS

WangB

2006 CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 42 464 469

21. LawnSD

MyerL

BekkerLG

WoodR

2007 Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21 335 341

22. AnglaretX

CheneG

AttiaA

ToureS

LafontS

1999 Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 353 1463 1468

23. YazdanpanahY

LosinaE

AnglaretX

GoldieSJ

WalenskyRP

2005 Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 19 1299 1308

24. GallantJE

DeJesusE

ArribasJR

PozniakAL

GazzardB

2006 Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 251 260

25. BenderMA

KumarasamyN

MayerKH

WangB

WalenskyRP

2008 Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 50 416 425

26. The Clinton Foundation 2008 Antiretroviral (ARV) price list. Available: http://www.clintonfoundation.org/download/?guid=62e82ddc-98de-102b-be34-001143e0d9b6. Accessed 11 December 2009

27. PhillipsAN

PillayD

MinersAH

BennettDE

GilksCF

2008 Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 371 1443 1451

28. BendavidE

YoungSD

KatzensteinDA

BayoumiAM

SandersGD

2008 Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 168 1910 1918

29. AVERT 2009 December 14 Universal access to AIDS treatment: targets and challenges. Available http://www.avert.org/universal-access.htm. Accessed 16 December 2009

30. ChengM

2009 December 2 WHO: Treat HIV patients sooner. Associated Press. Available: http://www.statesman.com/life/health-medical/who-treat-hiv-patients-sooner-90329.html. Accessed 22 November 2010

31. WanjaJ

2009 December 15 Kenya: AIDS drug to be withdrawn. Available: http://allafrica.com/stories/200912151096.html. AllAfrica Global Media. Accessed 16 December 2009

32. LawnSD

HarriesAD

AnglaretX

MyerL

WoodR

2008 Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22 1897 1908

33. LawnSD

HarriesAD

WoodR

2010 Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 5 18 26

34. Joint United Nations Programme on HIV/AIDS, World Health Organization 2007 Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva: World Health Organization. Available: http://whqlibdoc.who.int/publications/2007/9789241595568_eng.pdf. Accessed 3 August 2010

35. MellorsJW

MunozA

GiorgiJV

MargolickJB

TassoniCJ

1997 Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 946 954

36. BoulleA

OrrelC

KaplanR

Van CutsemG

McNallyM

2007 Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 12 753 760

37. ReidA

StohrW

WalkerAS

WilliamsIG

KityoC

2008 Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 46 1271 1281

38. GallantJE

ParishMA

KerulyJC

MooreRD

2005 Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40 1194 1198

39. ClearyS

BoulleA

McIntyreD

CoetzeeD

2004 Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Médecins Sans Frontières and the Health Systems Trust. Available: http://www.hst.org.za/uploads/files/arv_cost.pdf. Accessed 8 May 2009

40. BadriM

ClearyS

MaartensG

PittJ

BekkerLG

2006 When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 11 63 72

41. Gauteng Department of Health 2004 Gauteng Hospitals Numeric Report. Gauteng Province, South Africa